Moderna Dropped by 20% This Week -- Is It a Smart Buy Right Now?

Although the stock market was having a generally strong week, that isn't the case for vaccine technology company Moderna (MRNA -2.30%). The company, which was a leader in developing one of the initial COVID-19 vaccines, has plunged by 20% for the week as of mid-day Thursday.Disappointing sales guidance is the key reason for the plungeThe main reason for this week's decline is that Moderna lowered its 2025 full-year revenue guidance, and by a wide margin. The prior forecast called for $2.5 billion to$3.5 bi ...